
FDA says ‘dangerous' substance known as ‘gas station heroin' poses major risk to young people
The head of the U.S. Food and Drug Administration (FDA) is sounding the alarm on a dangerous drug referred to as "gas station heroin," that can lead to serious harm, including death.
FDA Commissioner Martin A. Makary sent a letter to his colleagues last week to draw their attention to what he called a "dangerous and growing health trend" facing the nation and young people. Makary said there is an increasing number of adverse events involving products that contain tianeptine.
Tianeptine, often called "gas station heroin," is sold in gas stations through a variety of products, despite the drug not being approved by the FDA.
"I am very concerned," Makary wrote. "I want the public to be especially aware of this dangerous product and the serious and continuing risk it poses to America's youth."
The products are typically sold at convenience stores, gas stations, vape shops and online retailers, and go by names like Tianaa, ZaZa, Neptune's Fix, Pegasus and TD Red.
Makary said the FDA is following the distribution and sale of products that contain tianeptine but called on his colleagues to disseminate information about the drug while appreciating the magnitude of its underlying danger.
Tianeptine is licensed and marketed in some countries as an atypical antidepressant, and in countries where it is approved, the typical labeled dose to treat depression is 12.5 mg orally, three times per day, Makary said.
When higher doses are taken, they can produce euphoria. Some countries have taken steps to restrict how tianeptine is prescribed or dispensed and have even revised the labels to warn people of its potential addiction.
In the U.S., though, tianeptine is not listed as part of the Controlled Substances Act.
The drug is often taken recreationally, though if stopped abruptly, users could experience withdrawal symptoms similar to those associated with opioid withdrawal – craving, sweating, diarrhea and more.
If tianeptine is ingested, Makary wrote, adverse events could include agitation, coma, confusion, death, drowsiness, hypertension, nausea, respiratory depression, sweating, tachycardia and vomiting.
Two years ago, New Jersey health officials warned that two products sold as dietary supplements in gas stations and online – Neptune's Elixir and ZaZa Red – had caused a spike in illnesses.
Between June and November 2023, there were 20 reported cases of tianeptine causing "severe clinical effects" in New Jersey, as noted in a Feb. 1 alert from the U.S. Centers for Disease Control and Prevention (CDC).
In 2023, the FDA posted an alert warning of the dangers of Neptune's Fix or any other product containing tianeptine.
"FDA has received severe adverse event reports after use of Neptune's Fix products, including seizures and loss of consciousness leading to hospitalization," the agency stated.
"FDA considers tianeptine to be a substance that does not meet the statutory definition of a dietary ingredient and is an unsafe food additive. The FDA is aware of several serious adverse event reports associated with tianeptine."
On Jan. 28, 2024, Neptune Resources, LLC, the maker of Neptune's Fix, issued a voluntary recall of its products due to the presence of tianeptine — but experts are warning that other products may also contain the drug.
Anyone who is using tianeptine or a product containing tianeptine and is experiencing withdrawal symptoms can call the National Poison Control Center at 1-800-222-1222 or seek emergency medical assistance, experts advised.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Entrepreneur
25 minutes ago
- Entrepreneur
The Power of Love in Action: A Portrait of Transformational Work That Heals and Empowers
With a presence that's more powerful than performance, Dr. Fang Miao is guiding women through emotional healing, personal safety, and true transformation. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media. She greets the world not with noise, but with quiet strength. In a time when fast advice and fleeting trends dominate, Dr. Fang Miao offers something rare: depth, presence, and transformation that lasts. A celebrated Women's Life Coach, educator, and social advocate, Dr. Miao has spent over two decades helping women not only find themselves—but truly return to themselves. As the President of the Association for the Protection of Asian Women in America, she has become a guiding force behind a movement that empowers from the inside out. Her recent book, Love to the Extreme: A Miracle Unfolds, is not just a publication—it's a map for the soul, inviting readers into a journey of awakening, emotional healing, and inner freedom. Dr. Miao's leadership transcends accolades—though her honors include the Stevie Award for Thought Leadership and a "Woman of the Year" nomination. What truly defines her impact is the quiet transformation of countless lives: women who have turned trauma into strength, confusion into clarity, and survival into soulful success. Elegant in prose yet grounded in real-life transformation, her latest work is not a philosophical musing—it is a field guide to deep, inner renewal. Rooted in nearly 20 years of coaching and experiential practice, the book distills personal transformation into a structured, three-phase process: cultivating self-awareness, deconstructing limiting beliefs, and realigning one's inner energy. "Fate is meant to be rewritten. What truly defines your destiny is not the moment you were born, but the moment you awaken to who you truly are." Drawing on techniques from family constellation, mind-body integration, and energy psychology, the book guides readers along a path that is both personal and universal. With case studies involving loss, anxiety, financial hardship, and healing, Love to the Extreme resonates not as distant theory, but as a roadmap for everyday miracles. Readers describe breakthroughs in relationships, renewed joy in parenting, emotional peace, and renewed career vitality. At its core, the book serves a dual purpose: a compassionate mirror and a practical method. It invites readers to shift their vibration—from contraction to expansion, from surviving to soulfully thriving. Beyond the book, Dr. Miao's vision comes alive through her community-based programs like the Women's Wellness & Fulfillment Retreat and Safe & Confident Living workshop series. These initiatives equip women with emotional regulation tools, personal safety skills, and inner strength—essentials for navigating a complex world. Her leadership has brought these programs to diverse communities, promoting well-being, self-worth, and safety. What sets Dr. Miao apart is her seamless integration of intellect and intuition. Drawing on neuroscience, trauma recovery, and spiritual insight, her teachings are both rigorous and deeply humane. Her philanthropic reach extends to underserved families and survivors of violence, providing practical support and hope. Love to the Extreme is not simply a book—it is an invitation to reimagine what's possible. For those ready to challenge internal limitations and step into clarity and boundless love, Dr. Miao offers not only mentorship, but a new way of being. In a world grappling with disconnection and uncertainty, her message is both balm and catalyst: healing is not a luxury—it is our natural state, waiting to be remembered. Her work offers more than inspiration—it provides a pathway to a more conscious, compassionate, and empowered world.
Yahoo
31 minutes ago
- Yahoo
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
– The International Society for Stem Cell Research ('ISSCR') 2025 Annual Meeting is the world's foremost gathering of stem cell and regenerative medicine leaders – – Updated data presented at ISSCR 2025 demonstrates >50% improvement in pain and function in a significant portion of cLDD subjects – – Number of evaluated subjects increases by more than two-fold since last update –– MELVILLE, N.Y., June 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ('BioRestorative,' 'BRTX' or the 'Company') (NASDAQ: BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease (cLDD). This data was shared at the prestigious ISSCR 2025 Annual Meeting in Hong Kong by Francisco Silva, Vice President of Research and Development. The U.S. Food and Drug Administration ('FDA') is requiring at least a greater than 30% improvement in function in the Oswestry Disability Index ('ODI') and a greater than 30% reduction in pain on the Visual Analog Scale ('VAS') in determining whether the clinical trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval. Key Highlights: Patient Numbers Growing: The number of subjects evaluated has increased from 15 to 36 since the Company's last press release — an important milestone toward full Phase 2 enrollment (up to 99 subjects). Compelling Clinical Signals: Over 74% of subjects showed >50% improvement in function (ODI) by 52 weeks; Over 72% of subjects reported >50% reduction in pain (VAS) by 52 weeks; Combined >50% improvement in both ODI and VAS measures was achieved by a meaningful portion of subjects across all timepoints. Excellent Safety Profile: No serious adverse events (SAEs) or dose-limiting toxicities reported between 26 and 104 weeks at the target dose (40 million cells). Strengthening Data: Each new data analysis has outperformed prior releases, highlighting an upward trend in efficacy markers. The following is a detailed breakdown of the subjects that had greater than 50% improvement in function, as measured by ODI, greater than 50% decrease in pain, as measured by VAS, and greater than 50% improvement in both ODI and VAS: Week Percentage of Subjects With >50% Average Improvement in ODI Percentage of Subjects With >50% Average Improvement in VAS Number of Subjects With >50% Average Improvement in Both ODI and VAS Baseline 0.00 % 0.00 % 0/36 12 67.57 % 73.82 % 5/25 26 74.04 % 76.94 % 6/15 52 74.63 % 72.35 % 8/10 104 75.13 % 68.54 % 2/4 'With every new analysis, our confidence grows that BRTX-100 is positioned to meet and potentially exceed the FDA's functional and pain reduction thresholds,' said Lance Alstodt, Chief Executive Officer of BioRestorative. 'We are excited by the trajectory of this material milestone and its potential to address a massive unmet need in chronic lower back pain — one of the largest global healthcare burdens. We believe this data moves us one step closer to bringing a much-needed, non-surgical therapeutic option to market and should add to further value enhancing inflection points in the near-term.' The data were presented as part of the Clinical Innovations track at ISSCR 2025, an event that attracts the world's top stem cell and regenerative medicine researchers, clinicians, and investors. About the BRTX-100 Phase 2 Trial BRTX-100 is a novel, autologous cell-based therapy designed to treat patients suffering from painful lumbosacral disc degeneration. The Phase 2 trial is a randomized, double-blinded, placebo-controlled study that will enroll up to 99 subjects at 16 leading U.S. sites. Subjects are randomized 2:1 to receive either BRTX-100 or placebo via a minimally invasive outpatient procedure. About BioRestorative Therapies, Inc. BioRestorative ( develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration ('FDA') Investigational New Drug ('IND') clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain. • Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells ('BADSC') to generate brown adipose tissue ('BAT'), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss. • BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements. CONTACT: Stephen KilmerInvestor RelationsDirect: (646) 274-3580 Email: skilmer@

Epoch Times
40 minutes ago
- Epoch Times
FDA Approves Moderna's RSV Vaccine for Some Younger Adults, Company Says
Federal regulators approved Moderna's vaccine against Respiratory Syncytial Virus (RSV) for some adults as young as 18, the company said on June 12. The Food and Drug Administration (FDA) expanded approval of the shot to people aged 18 to 59 who face an increased risk from RSV, a virus that typically causes cold-like symptoms, Moderna